We speak to McCann Health to find out how the agency is adapting to a world where healthcare communications are becoming broader and more innovative than ever before.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh